Vigilare Wealth Management increased its stake in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 63.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,965 shares of the biotechnology company’s stock after acquiring an additional 13,245 shares during the quarter. Vigilare Wealth Management’s holdings in Trillium Therapeutics were worth $500,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. VR Adviser LLC boosted its stake in shares of Trillium Therapeutics by 6.1% in the third quarter. VR Adviser LLC now owns 7,204,577 shares of the biotechnology company’s stock valued at $102,377,000 after purchasing an additional 414,577 shares during the period. PFM Health Sciences LP raised its position in Trillium Therapeutics by 31.7% during the third quarter. PFM Health Sciences LP now owns 1,126,325 shares of the biotechnology company’s stock valued at $16,005,000 after buying an additional 271,055 shares during the period. Schonfeld Strategic Advisors LLC grew its stake in Trillium Therapeutics by 42.5% in the third quarter. Schonfeld Strategic Advisors LLC now owns 569,154 shares of the biotechnology company’s stock valued at $8,088,000 after purchasing an additional 169,654 shares in the last quarter. Two Sigma Advisers LP grew its stake in Trillium Therapeutics by 8.2% in the second quarter. Two Sigma Advisers LP now owns 346,000 shares of the biotechnology company’s stock valued at $2,799,000 after purchasing an additional 26,200 shares in the last quarter. Finally, Blair William & Co. IL grew its stake in Trillium Therapeutics by 44.4% in the third quarter. Blair William & Co. IL now owns 338,770 shares of the biotechnology company’s stock valued at $4,814,000 after purchasing an additional 104,215 shares in the last quarter. Hedge funds and other institutional investors own 66.60% of the company’s stock.
In other news, CFO James T. Parsons sold 8,505 shares of the business’s stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $15.79, for a total transaction of $134,293.95. Following the completion of the sale, the chief financial officer now owns 8,505 shares in the company, valued at $134,293.95. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Penka Petrova sold 2,708 shares of the business’s stock in a transaction that occurred on Thursday, January 7th. The stock was sold at an average price of $14.71, for a total value of $39,834.68. Following the sale, the insider now owns 2,708 shares of the company’s stock, valued at approximately $39,834.68. The disclosure for this sale can be found here. Insiders have sold 11,797 shares of company stock valued at $183,005 in the last quarter.
A number of brokerages have commented on TRIL. Craig Hallum boosted their target price on Trillium Therapeutics from $15.00 to $21.00 in a research note on Wednesday, November 18th. Zacks Investment Research downgraded Trillium Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, October 16th. HC Wainwright upped their price target on Trillium Therapeutics from $16.50 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, November 18th. Evercore ISI initiated coverage on Trillium Therapeutics in a research note on Monday, October 12th. They set an “outperform” rating and a $28.00 price target for the company. Finally, Bloom Burton downgraded Trillium Therapeutics from a “buy” rating to an “accumulate” rating in a research note on Tuesday, December 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Trillium Therapeutics has a consensus rating of “Buy” and an average target price of $17.85.
TRIL stock traded up $0.51 during midday trading on Thursday, reaching $15.02. 22,745 shares of the company’s stock traded hands, compared to its average volume of 1,299,993. The company has a 50-day simple moving average of $14.58 and a two-hundred day simple moving average of $12.30. Trillium Therapeutics Inc. has a 1-year low of $2.26 and a 1-year high of $20.96. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -5.90 and a beta of 2.04.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its quarterly earnings results on Sunday, November 15th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.33). On average, sell-side analysts anticipate that Trillium Therapeutics Inc. will post -1.53 earnings per share for the current fiscal year.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides.
Further Reading: Why do commodities matter?
Want to see what other hedge funds are holding TRIL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR).
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.